Free Trial

MIRA Pharmaceuticals (MIRA) Competitors

MIRA Pharmaceuticals logo
$1.23 +0.02 (+1.65%)
Closing price 05/22/2025 04:00 PM Eastern
Extended Trading
$1.24 +0.01 (+0.41%)
As of 05/22/2025 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MIRA vs. ORMP, ANIX, CLLS, CLYM, PLRX, SNTI, GALT, ADAG, OCX, and GNTA

Should you be buying MIRA Pharmaceuticals stock or one of its competitors? The main competitors of MIRA Pharmaceuticals include Oramed Pharmaceuticals (ORMP), Anixa Biosciences (ANIX), Cellectis (CLLS), Climb Bio (CLYM), Pliant Therapeutics (PLRX), Senti Biosciences (SNTI), Galectin Therapeutics (GALT), Adagene (ADAG), OncoCyte (OCX), and Genenta Science (GNTA). These companies are all part of the "pharmaceutical products" industry.

MIRA Pharmaceuticals vs.

Oramed Pharmaceuticals (NASDAQ:ORMP) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership, community ranking and valuation.

Oramed Pharmaceuticals has higher revenue and earnings than MIRA Pharmaceuticals. Oramed Pharmaceuticals is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oramed Pharmaceuticals$1.34M65.54$5.53M-$0.44-4.89
MIRA PharmaceuticalsN/AN/A-$11.98M-$0.51-2.41

Oramed Pharmaceuticals' return on equity of -7.27% beat MIRA Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Oramed PharmaceuticalsN/A -7.27% -6.20%
MIRA Pharmaceuticals N/A -337.44%-280.58%

12.7% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 13.7% of Oramed Pharmaceuticals shares are held by company insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

MIRA Pharmaceuticals has a consensus price target of $14.00, indicating a potential upside of 1,038.21%. Given MIRA Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe MIRA Pharmaceuticals is more favorable than Oramed Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oramed Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
MIRA Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.33

In the previous week, Oramed Pharmaceuticals had 2 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 4 mentions for Oramed Pharmaceuticals and 2 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 0.00 beat Oramed Pharmaceuticals' score of -0.53 indicating that MIRA Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oramed Pharmaceuticals
0 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Negative
MIRA Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Oramed Pharmaceuticals has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Comparatively, MIRA Pharmaceuticals has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500.

Oramed Pharmaceuticals received 316 more outperform votes than MIRA Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave MIRA Pharmaceuticals an outperform vote while only 71.85% of users gave Oramed Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Oramed PharmaceuticalsOutperform Votes
319
71.85%
Underperform Votes
125
28.15%
MIRA PharmaceuticalsOutperform Votes
3
100.00%
Underperform Votes
No Votes

Summary

Oramed Pharmaceuticals beats MIRA Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get MIRA Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for MIRA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MIRA vs. The Competition

MetricMIRA PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$20.81M$6.47B$5.33B$8.39B
Dividend YieldN/A2.64%5.21%4.11%
P/E Ratio-2.209.0626.7119.71
Price / SalesN/A251.51386.08120.53
Price / CashN/A65.8538.2534.62
Price / Book4.106.456.774.50
Net Income-$11.98M$143.98M$3.23B$248.22M
7 Day Performance-15.17%0.38%0.48%-0.78%
1 Month Performance33.55%2.14%9.10%11.53%
1 Year Performance39.77%-0.33%18.56%8.99%

MIRA Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MIRA
MIRA Pharmaceuticals
1.3984 of 5 stars
$1.23
+1.7%
$14.00
+1,038.2%
+34.3%$20.81MN/A-2.202
ORMP
Oramed Pharmaceuticals
1.8017 of 5 stars
$2.14
-0.5%
N/A-6.5%$87.42M$1.34M19.4510
ANIX
Anixa Biosciences
1.7202 of 5 stars
$2.70
+1.9%
$9.00
+233.3%
+0.0%$86.93M$210,000.00-6.925
CLLS
Cellectis
2.7847 of 5 stars
$1.55
-1.9%
$6.67
+330.1%
-46.2%$86.16M$47.63M-1.19290News Coverage
Analyst Downgrade
CLYM
Climb Bio
2.7008 of 5 stars
$1.27
-1.6%
$10.00
+687.4%
N/A$85.82MN/A-0.609News Coverage
Analyst Forecast
Analyst Revision
PLRX
Pliant Therapeutics
4.2506 of 5 stars
$1.35
-2.2%
$13.31
+886.1%
-90.6%$84.71M$1.58M-0.4090News Coverage
Positive News
SNTI
Senti Biosciences
1.6937 of 5 stars
$3.24
+1.9%
$12.00
+270.4%
-16.3%$84.50M$2.56M-0.214
GALT
Galectin Therapeutics
1.2113 of 5 stars
$1.33
+3.9%
$11.00
+727.1%
-58.8%$84.03MN/A-1.829Earnings Report
ADAG
Adagene
1.7913 of 5 stars
$1.77
flat
$8.00
+352.0%
-37.7%$83.39M$103,204.000.00260News Coverage
OCX
OncoCyte
2.6017 of 5 stars
$2.80
+0.4%
$4.42
+57.7%
+18.2%$80.08M$3.84M-0.79120Analyst Forecast
GNTA
Genenta Science
1.4863 of 5 stars
$4.37
+2.9%
$25.00
+471.6%
+34.4%$80MN/A0.007Gap Up

Related Companies and Tools


This page (NASDAQ:MIRA) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners